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In a previous editorial note, we presented the “do’s” and “don’ts” of observational studies, 
stressing the importance of transparent reporting of study methodology and correct 
terminology to avoid inference of effects and impact. 1 We still receive many observational 
studies that are poorly presented. As for any study design, good quality reporting 
significantly increases chances of publication. 
 
The STROBE checklist and statement address the reporting requirements of observational 
studies. 2 We expand on the STROBE statement’s methods section to explain its items with 
reference to observational cohort studies in infectious diseases and to provide 
recommendations on the preferred order of item presentation in the methods section in 
CMI. The required methods components are shown in the table and explained in text. 
 
Study design: The STROBE statement advises that authors "refrain from simply calling a 
study “prospective” or “retrospective"… and recommend that, whenever authors use these 
words, they define what they mean". 2 A retrospective study could have been prospectively 
defined, before start of data collection and before observation of the outcome, significantly 
strengthening it. A "prospective" study can collect only data documented in patients' charts 
(not very different from a well-planned retrospective study) or could include a measurement 
performed specifically for the purpose of study, adding to what would have been available 
from patients' charts alone. We sometime receive "prospective studies" defined as such 
because they are based on prospective surveillance systems designed for purposes other 
than the study question. These should be defined as retrospective cohort studies assessing 
prospectively collected data, if using these terms. Alternatively, declare transparently that 
the study question was formulated only after the data had been collected. Thus, a study 
assessing the association between pre-operative oral antibiotics and prosthetic joint 
infections appropriately reported that "This retrospective study was performed in… and that 
Patients, who had undergone an elective primary hip or knee replacement between 
September 2002 and December 2013 were identified from the local prospective joint 
replacement database." 3 There is a prospective registry of prosthetic joint replacement, but 
the analysis of oral antibiotics and PJI was retrospective. 
 
We expect to be told whether the protocol and the research question were framed before 
or after the creation of data; whether the identification of patients was done in real time or 
in retrospect; whether data were collected prospectively, at pre-set times defined in the 
protocol; or in real time from files, patients and health care personnel; or in retrospect from 
files. Registering the study before outcomes have been determined and before start of data 
collection would lend support to the study and strengthen the confidence that outcome 
definitions or other data were not manipulated to show significance. 4 A study showed an 
association between an antibiotic stewardship intervention and lower antibiotic in leukemia 
unit. 5 Registering it before start of the intervention, would have ensured us that the study 
was not conducted because a reduction in antibiotic usage was observed.  
 
Setting: Describe where the study was conducted and between what years. Further details 
on the setting should be provided as relevant in the context of the study. For example, a 
study examining the association between imipenem therapeutic drug monitoring (TDM) and 
clinical outcomes described that "Currently beta-lactam TDM is employed mainly by 
intensive care, infectious disease, and haematology-oncology specialists. It is performed on 
working days and is unavailable at night and on weekends; turnaround time for samples 
drawn on workdays is roughly 7 hours…". 6  A study examining whether contact isolation in 
single-patient rooms is associated with less transmission of fluroquinolone- and 
cephalosporin-resistant Escherichia coli described the local hand-hygiene practice in the 
study setting. 7  In many studies, local epidemiology and resistance prevalence are important 
to understand the study and its external implications. Thus, in this same study on single-
patient rooms, the baseline prevalence of fluroquinolone and cephalosporin-resistant E. coli 
is important, since the study results might not be applicable to settings with very different 
extended spectrum beta-lactamase (ESBL) endemicity levels. 
 
Ethics: An ethics statement is mandatory for all observational cohort studies. Even if the 
study reports the results of standard surveillance, infection-control interventions, or changes 
in clinical practice, reporting should be approved by an ethics committee. If local regulations 
allow an observational study to be conducted without patient consent, or without the need 
for Ethics Committee approval, please say so explicitly.   
 
Participants: Study eligibility criteria should be clearly presented. To check whether your 
definitions are clear, examine (or preferably let a colleague tell you) whether they are 
replicable, whether applying the definitions to the next patient will determine eligibility. 
Describe how potentially eligible patients were detected and how inclusion/exclusion 
criteria were applied. Participant numbers do not belong in the methods section, but should 
be described in the results section (e.g. in a flowchart), following the methods of patient 
detection and identification. 
 
Exposure: An exposure variable is the equivalent of an intervention in a randomized 
controlled trial: e.g.  treatment (of C. difficile) with fidaxomixin or vancomycin, 8 combination 
therapy with ciprofloxacin (for Escherichia coli meningitis in infants), 9  treatment with 
colistin vs. colistin-tigecycline (of A. baumannii bacteremia), an antibiotic stewardship 
program 5, appropriate empirical antibiotic treatment. 10 It might also relate to a patient 
characteristic that is observed: e.g. P. aeruginosa colonization (in patients with chronic 
obstructive pulmonary disease), 11 carbapenemase-producing Enterobacteriaceae 
colonization (among patients undergoing liver transplantation) 12. It is the key risk factor on 
which the study focuses.  Descriptive studies that do not perform a risk factor analysis do 
not have an exposure variable. Studies assessing risk factors may not have a single, pre-
defined, exposure variable: e.g. a study that examined predictors for mortality among 
patients with drug-susceptible tuberculosis in the Netherlands, did not define key risk 
factor/s as an exposure. 13  
 
If examining an exposure, the exposure must be well-defined, well enough to be replicable 
and applicable. For example, observational studies comparing monotherapy to combination 
therapy (exposure) deal inherently with the problem that treatments were not standardized. 
14 A good description of the exposure should convince us that the patients in the 
combination group did indeed receive the specified combination therapy, while the others 
did not. The definition should be clear enough to be applied to further patients. The study 
assessing combination therapy with ciprofloxacin for neonates with E. coli meningitis 
described that "Concerning ciprofloxacin treatment, we recorded the doses used, duration 
of treatment and delay between diagnosis and adjunct ciprofloxacin therapy." 9 This does 
not allow us to replicate the intervention. For full clarity, the definition should have 
addressed the start time relative to meningitis diagnosis, dosing and minimal duration of the 
exposure, as it would have had to in an interventional study where the treatment protocol 
has to be clearly defined. The study assessing the management of A. baumannii bacteraemia 
reported that "The exposure variable was targeted treatment with monotherapy (colistin) 
versus combined therapy (colistin plus tigecycline). Only patients who began targeted 
therapy with colistin in the first 3 days following blood cultures and did not receive any 
other drug with potential activity against A. baumannii were included. The inclusion criterion 
for patients in the combination therapy group was the administration of tigecycline for >50% 
of the total treatment time." 15 The doses of the drugs were defined. This is a clear 
description of how patients were assigned to combination therapy. 
 
Outcome(s): The primary and secondary outcomes should be explicitly defined, addressing 
the time point of assessment. If the analysis is based on regression analysis, the primary 
outcome should concord with the dependent variable of the regression.  
 
Other study variables:  In traditional epidemiological teaching, the confounder is associated 
both with the exposure and the outcome, without being on the causal pathway. For 
example, being Asian or black was identified as a strong risk factor for ESBL colonization on 
admission screening to a hospital in London. 16 Clearly, this is not the cause for ESBL 
colonization. Confounders such as recent antibiotic use, travel, living conditions or other 
factors actually explain this association. An "effect" modifier (or association modifier for 
observational studies) is a variable that explains variability in the magnitude of the 
association between the exposure and the outcome. For example, in an observational study 
assessing treatment duration for Staphylococcus aureus bacteremia and 90-day mortality, 
complicated or uncomplicated bacteremia affected the magnitude of the association. 17 
Sometimes it might be difficult to classify a variable as potential confounder or effect 
modifiers; expert knowledge and careful judgement is necessary, to allow the correct 
analysis to be applied. Predictors are other variables that predict the outcome, and in many 
studies other variables are collected to describe the cohort. It is critical to anticipate 
potential confounders and effect modifiers and plan to collect these, because we or the 
reviewers will probably ask for them. When reporting, while it is not mandatory to 
distinguish between different types of variables, it might be advantageous to highlight the 
variables that were collected specifically considering confounding and effect modification. 
Microbiology: Microbiological methods for pathogen identification and resistance testing 
are special to studies in infectious diseases. Address these if relevant. 
Data sources/measurements: We prefer separation between the study variable definitions 
and their data sources. Data sources of all study variables described above should be 
presented. In observational studies, study participants are often drawn from a larger 
database such as a microbiology database or admission/discharge databases. In this case, 
describe the original database and how patients were selected from it. The data sources for 
the exposure variable should reflect the confidence that patients were exposed to the 
intended intervention or had the exposure characteristic. The exposure variable in a case-
control study assessing risk factors for Clostridioides difficile infection (CDI) was remote 
cholecystectomy. The authors report that "manual chart review was necessary to accurately 
ascertain distant cholecystectomy". 18 Indeed, obtaining the data merely from admission/ 
discharge diagnoses would probably not have been precise. Outcome data sources might be 
different from other variables' data sources; methods to collect post-discharge outcome 
data should be described.  
While we suggest reporting of all data sources in one section, refrain from repetition if 
patient selection methods were previously presented under participants, and if exposure or 
outcome sources were described under their respective items. 
Sample size/power: A sample size justification is required. The study comparing fidaxomicin 
to vancomycin for CDI reported: "Assuming a 35% combined clinical failure/recurrence rate 
for vancomycin, at least 134 participants were necessary in each arm to find a 20% 
combined clinical failure/recurrence rate for fidaxomicin…". 8 This is a calculation 
appropriate for a randomized trial, not for an observational study that requires more than a 
crude comparison between fidaxomicin vs. vancomycin. Nonetheless, this estimate 
strengthens the authors’ conclusions on the lack of difference between the 213 patients 
treated with fidaxomixin compared to 639 patients treated with vancomycin after 
propensity-score-matching. Since sample size calculation for prediction models and other 
observational studies is not standardized, we will accept observational studies without a 
formal sample size calculation, but we nonetheless require reporting of how investigators 
arrived at the final sample size (e.g. 10,411 confirmed Crimean- Congo haemorrhagic fever 
cases were reported between 2004 and 2017 in Turkey 19). A justification of why an 
available, known, sample of patients is sufficient to answer the study question will 
strengthen the study, especially when the available sample is small. In any case, we will 
appraise whether the sample is reasonable to answer the study question based on precision 
of the results (confidence interval spread) and require interpretation of negative results 
considering the sample size/ power. Note that the number of included patients does not 
belong in the methods section, unless justifying the number of patients in a known available 
sample (as in the Crimean- Congo haemorrhagic fever example).  
Statistical methods: Make sure to define all the analyses presented in the manuscript in the 
methods section. We expect separation between skewed continuous data (e.g. 
hospitalization duration) and normally-distributed data. Statistical assumptions and variables 
planned for the construct of regression and propensity score models should be explicitly 
described. See also our guidance on reporting of multivariable analyses in CMI [16]. 
Subgroup and sensitivity analyses: Important association modifiers can be addressed 
through subgroup analyses and known methodological limitations can be addressed through 
sensitivity analyses. Defining these in the methods is necessary if performing subgroup or 
sensitivity analyses. Importantly, we would like to know whether these were planned in 
advance or driven by the results. 
 
While, all the above relates to the final stage of reporting a completed study, it cannot be 
stressed enough how writing the protocol methods according to reporting guidelines will 
improve the study methodology and allow high-quality reporting at the end. Addressing 
carefully each item of the checklist will raise questions best addressed before start of the 
study. A study planning to examine risk factors can be strengthened by defining 
prospectively one (or few) risk factor(s) of interest that led to the risk-factor analysis 
Defining an exposure variable allows hypothesis generation and provides a focus that lacks 
in studies exploring a dearth of potential risk factors. For example, a study assessing risk 
factors for carbapenemase-producing enterobacteriaceae (CPE) infections following liver 
transplantation, hypothesized that colonization by CPE before or after transplantation is a 
significant risk factor, defining it as the exposure. 12 The definition of an "intervention" type 
of exposure will determine the number of exposed patients; at the protocol stage the 
researchers can consider strict criteria for an informative exposure or broader criteria with 
more exposed patients. When defining the outcomes, authors might want to consult 
consensus statements on the relevant outcomes, such as the COMET (http://www.comet-
initiative.org/) and others. Sample size calculations can only be performed prospectively, 
and guidance for sample size/power calculations for prediction models have been proposed. 
20, 21 At the protocol stage an item should be added to the methods section, that in the full 
report is addressed in the discussion section: potential biases. An explicit consideration of 
any biases specific to the study and any measures taken to prevent/counteract bias would 
enhance robustness of results and causal inference. A pre-defined statistical analysis plan, 
analogous to that required for clinical trials, would increase quality of research and facilitate 
the final reporting. 22 
 
A methods section organized according to this scheme is easier to follow and ensures 
complete reporting. An unorganized methods section leads to missing information, 
repetitions and inconsistencies. Although seemingly a long list of items, writing in line with 
the STROBE scheme actually allows significant shortening of the text to the concise format 
necessary for scientific reporting. The items can be presented under subheadings or the text 
can flow more smoothly, as long as all the items are addressed and preferably in the above 
order. The STROBE scheme should be applied to the methods section of the abstract, to the 










Checklist: Expanded methods of observational cohort studies 
 
Study design In addition to specifying the study as an observational cohort study, 
clarify whether the submitted study was planned before data 
collection, which parts of the data collection were prospective and 
which were retrospective. 
Setting Describe the study location(s) and setting, including start and end 
dates. No need to repeat these data in results. Describe the relevant 
epidemiology, infection control or other management features of 
the setting, as relevant in the study context. 
Ethics and 
registration 
Provide a statement addressing the ethical approval of the study, 
whether informed consent was necessary and registration details if 
the study was registered. 
Participants Define the inclusion and exclusion criteria of the study. 
Exposure When examining an "intervention", treatment or specific patient 
characteristic, define this as the exposure variable and provide a 




Define all outcomes reported in the study, specifying which is the 
primary outcome, including the time point at which the outcomes 
were measured. In observational studies performing regression 
analysis, this is also the dependent variable and can be presented as 
such.  
Other variables Other study variables may include confounders, association 
modifiers, other predictors and cohort descriptors. Justify 
dichotomization of continuous variables and describe whether they 
were planned ahead of analysis. 
Microbiology Provide the microbiological methods of the study, if relevant. 
Data sources/ 
measurements 
Describe the sources of data, including participant identification, 
outcome data, exposure and study variables. Address the methods 
to collect missing data or end of follow-up data (such as post-
discharge outcomes). Describe how measurements were performed.  
Sample size/ 
power 
Provide a sample size calculation. If none was performed, describe 
how you arrived at the final sample size. Unless known before the 
study, in the context of power justification, do not provide data on 
the number of included patients in the methods section. 
Statistical 
methods 
Describe all statistical methods, including those used to control for 
confounding and time-dependent exposures. Explain how missing 




Define subgroup and sensitivity analyses, if performed. Describe 
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